Know Cancer

or
forgot password

A Phase I, Open-Label, Multi-centre Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of AZD8330 in Patients With Advanced Malignancies


Phase 1
18 Years
N/A
Not Enrolling
Both
Cancer

Thank you

Trial Information

A Phase I, Open-Label, Multi-centre Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of AZD8330 in Patients With Advanced Malignancies


Inclusion Criteria:



- Cancer which is refractory to standard therapies, or no therapies exist;

Exclusion Criteria:

- Participated in radiotherapy, biological or chemotherapy within 21 days prior to
study start;

- Hasn't participated in investigation drug study within 30 days;

- Brain metastases/spinal cord compression unless treated and stable,

- Off steroids/anticonvulsants.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To assess safety and tolerability of AZD8330 in patient with advanced malignancies.

Principal Investigator

Emerging Oncology Medical Science Director, MD

Investigator Role:

Study Director

Investigator Affiliation:

AstraZeneca

Authority:

United States: Food and Drug Administration

Study ID:

D1536C00001

NCT ID:

NCT00454090

Start Date:

March 2007

Completion Date:

March 2011

Related Keywords:

  • Cancer
  • Advanced Malignancies
  • Neoplasms

Name

Location

Research SiteAllentown, Pennsylvania  
Research SiteAbilene, Texas